Electromagnetic localization developer Calypso Medical Technologies has been granted 510(k) clearance by the U.S. Food and Drug Administration for its Calypso 4D localization system.
The product, which utilizes proprietary electromagnetic technology in conjunction with transponders implanted in the prostate, is designed to provide accurate and continuous tumor location information during external-beam radiation therapy (EBRT) without adding ionizing radiation, according to the Seattle-based firm.
By AuntMinnie.com staff writers
August 8, 2006
Related Reading
Calypso launches rad therapy trial, July 21, 2005
Calypso, Philips team up, October 5, 2004
Calypso reports IDE progress at AAPM show, July 28, 2004
Copyright © 2006 AuntMinnie.com